Literature DB >> 17241755

Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer.

M Rex Cheung1, Susan L Tucker, Lei Dong, Renaud de Crevoisier, Andrew K Lee, Steven Frank, Rajat J Kudchadker, Howard Thames, Radhe Mohan, Deborah Kuban.   

Abstract

BACKGROUND: We sought to identify the bladder dose-volume factors associated with an increased risk of late urinary toxicity among prostate cancer patients treated with radiotherapy. METHODS AND MATERIALS: This retrospective analysis included data from 128 prostate cancer patients treated on protocol with 2 Gy/fraction to 46 Gy followed by a boost to 78 Gy. The endpoint for this analysis was Grade 1 or greater late genitourinary (GU) toxicity occurring within two years of treatment. The Lyman-Kutcher-Burman, mean dose, threshold dose, and hottest volume models were fitted to the toxicity data using the maximum likelihood method.
RESULTS: Model fits based on dose-volume histograms tended to fit the toxicity data better than models based on dose-wall histograms. The hottest volume (hotspot) model was found to be the best-fitting model investigated. The best fit was for the hottest 2.9% of bladder (95% CI, 1.1-6.8%). This model has an area under the receiver operating characteristic curve of 0.74. The hotspot model separated the patients into clinically meaningful subgroups with approximately 25% of the patients who received <78 Gy to the hottest 2.9% of bladder had GU toxicity at eight years compared with approximately 50% when the dose was > or =78 Gy (p = 0.002).
CONCLUSION: This provides the first evidence supporting that bladder "hotspots" are related to GU toxicity within two years after external beam radiotherapy for prostate cancer. Confirming data are needed from other investigators. Particular attention should be given to hotspots higher than 78 Gy in bladder in radiation treatment planning.

Entities:  

Mesh:

Year:  2007        PMID: 17241755      PMCID: PMC2081969          DOI: 10.1016/j.ijrobp.2006.10.042

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

1.  Patterns of Care Studies: Past, Present, and Future.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1997-04       Impact factor: 5.934

2.  Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy.

Authors:  Susan L Tucker; Lei Dong; Rex Cheung; Jennifer Johnson; Radhe Mohan; Eugene H Huang; H Helen Liu; Howard D Thames; Deborah Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-12-01       Impact factor: 7.038

3.  Rectal bleeding after conformal 3D treatment of prostate cancer: time to occurrence, response to treatment and duration of morbidity.

Authors:  T Teshima; G E Hanks; A L Hanlon; R S Peter; T E Schultheiss
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

4.  Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.

Authors:  M J Zelefsky; D Cowen; Z Fuks; M Shike; C Burman; A Jackson; E S Venkatramen; S A Leibel
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

5.  Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.

Authors:  Susan L Tucker; H Helen Liu; Shulian Wang; Xiong Wei; Zhongxing Liao; Ritsuko Komaki; James D Cox; Radhe Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-11       Impact factor: 7.038

6.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

7.  Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.

Authors:  Zachariah A Allen; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Brian Kurko; Richard L Anderson; Brian C Murray; Robert W Galbreath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

8.  Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer.

Authors:  Susan L Tucker; Rex Cheung; Lei Dong; H Helen Liu; Howard D Thames; Eugene H Huang; Deborah Kuban; Radhe Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

9.  Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy.

Authors:  Michele Albert; Clare M Tempany; Delray Schultz; Ming-Hui Chen; Robert A Cormack; Sanjaya Kumar; Mark D Hurwitz; Clair Beard; Kemal Tuncali; Michael O'Leary; George P Topulos; Kristin Valentine; Lynn Lopes; Angela Kanan; Daniel Kacher; James Rosato; Hanne Kooy; Ferenc Jolesz; David L Carr-Locke; Jerome P Richie; Anthony V D'Amico
Journal:  Cancer       Date:  2003-09-01       Impact factor: 6.860

10.  Erectile dysfunction and radiation dose to penile base structures: a lack of correlation.

Authors:  Ugur Selek; Rex Cheung; Mingfwu Lii; Pamela Allen; Roy E Steadham; Terry R Vantreese; Darren J Little; Isaac I Rosen; Deborah Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

View more
  29 in total

1.  A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study.

Authors:  M Fatyga; J F Williamson; N Dogan; D Todor; J V Siebers; R George; I Barani; M Hagan
Journal:  Med Phys       Date:  2009-09       Impact factor: 4.071

2.  Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.

Authors:  Thomas P Kole; Michael Tong; Binbin Wu; Siyuan Lei; Olusola Obayomi-Davies; Leonard N Chen; Simeng Suy; Anatoly Dritschilo; Ellen Yorke; Sean P Collins
Journal:  Acta Oncol       Date:  2015-05-14       Impact factor: 4.089

3.  A novel nitroxide is an effective brain redox imaging contrast agent and in vivo radioprotector.

Authors:  Ryan M Davis; Anastasia L Sowers; William DeGraff; Marcelino Bernardo; Angela Thetford; Murali C Krishna; James B Mitchell
Journal:  Free Radic Biol Med       Date:  2011-05-25       Impact factor: 7.376

4.  Image guided dose escalated prostate radiotherapy: still room to improve.

Authors:  Jarad M Martin; Andrew Bayley; Robert Bristow; Peter Chung; Mary Gospodarowicz; Cynthia Menard; Michael Milosevic; Tara Rosewall; Padraig R Warde; Charles N Catton
Journal:  Radiat Oncol       Date:  2009-11-03       Impact factor: 3.481

5.  Using cone-beam computed tomography to evaluate the impact of bladder filling status on target position in prostate radiotherapy.

Authors:  Chiao-Ling Tsai; Jian-Kuen Wu; Chun-Wei Wang; Feng-Ming Hsu; Ming-Kuen Lai; Jason Chia-Hsien Cheng
Journal:  Strahlenther Onkol       Date:  2009-09-12       Impact factor: 3.621

6.  A predictive model to guide management of the overlap region between target volume and organs at risk in prostate cancer volumetric modulated arc therapy.

Authors:  Malcolm D Mattes; Jennifer C Lee; Sara Elnaiem; Adel Guirguis; N C Ikoro; Hani Ashamalla
Journal:  Radiat Oncol J       Date:  2014-03-27

Review 7.  Proton radiation for localized prostate cancer.

Authors:  John J Coen; Anthony L Zietman
Journal:  Nat Rev Urol       Date:  2009-05-12       Impact factor: 14.432

8.  Evaluation of the deformation and corresponding dosimetric implications in prostate cancer treatment.

Authors:  Ning Wen; Carri Glide-Hurst; Teamour Nurushev; Lei Xing; Jinkoo Kim; Hualiang Zhong; Dezhi Liu; Manju Liu; Jay Burmeister; Benjamin Movsas; Indrin J Chetty
Journal:  Phys Med Biol       Date:  2012-08-03       Impact factor: 3.609

9.  Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.

Authors:  B Henriques de Figueiredo; C Zacharatou; S Galland-Girodet; J Benech; H De Clermont-Gallerande; F Lamare; M Hatt; L Digue; E De Mones del Pujol; P Fernandez
Journal:  Strahlenther Onkol       Date:  2014-09-23       Impact factor: 3.621

10.  An assessment of PTV margin based on actual accumulated dose for prostate cancer radiotherapy.

Authors:  Ning Wen; Akila Kumarasiri; Teamour Nurushev; Jay Burmeister; Lei Xing; Dezhi Liu; Carri Glide-Hurst; Jinkoo Kim; Hualiang Zhong; Benjamin Movsas; Indrin J Chetty
Journal:  Phys Med Biol       Date:  2013-10-18       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.